Publications
Specialty
Search
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
07/10/2024
Sensome’s clot-sensing guidewire integrates the world’s smallest electrical impedance sensor with machine learning and is being developed to instantly identify clot composition and clot length in real-time in order to inform treatment approach during mechanical thrombectomy.
First Report Managed Care
07/10/2024
Already challenged with cost, care, and administrative pressures, health care organizations are now staring down a daunting talent supply-and-demand gap. This shortage will negatively affect affordability and access to care for consumers and bears profitability risks for providers, payers, and other health care stakeholders.
First Report Managed Care
07/10/2024
A computational method has been developed to identify HIV-1 broadly neutralizing antibodies (bNAbs) from non-selected immune repertoires, researchers reported in the journal Nature Communications.
EMSWorld
07/10/2024
A 911 call brings in a 41-year-old woman with a fever, rash, and muscle aches. Blair Bigham works to uncover signs of infection and dives into the risk of tick-borne diseases.
Podiatry Today
07/10/2024
Dr. DiDomenico details his experience with minimally invasive bunion surgery, including surgical and postop pearls, including when to weight-bear.
Vascular Disease Management, IO Learning
07/09/2024
Transit Scientific Press Release
Park City, Utah USA, July 9, 2024 – Transit Scientific, a Utah-based medical device company specializing in innovative solutions for vascular
The Dermatologist
07/09/2024
The US Food and Drug Administration has approved roflumilast cream 0.15% for the treatment of mild to moderate atopic dermatitis in adults and children aged 6 and older.
First Report Managed Care, Population Health
07/09/2024
In this blog the HMP Market Access Intelligence team breaks down the knowns and unknowns of the Inflation Reduction Act's impact on drug price negotiations and what the future may hold.
Wound Care
07/09/2024
Industry thought leader Dr. Paul Kim and Perceptive Solutions president Mark Lacerte discuss WoundZoom, an advanced software platform designed to image and track healing, accelerate clinical workflow, generate real-time reports and analytics, and elevate outcomes. Seamlessly connected to your EHR, WoundZoom empowers practice excellence.
Oncology
07/09/2024
Phase 2 results from the SELECT study demonstrated that weekly carfilzomib, pomalidomide, and dexamethasone treatment showed efficacy and tolerability among patients with relapsed/refractory multiple myeloma.
Oncology
07/09/2024
According to a phase 2 study, selumetinib demonstrated efficacy among both children and adults with NF1 and inoperable plexiform neurofibromas, and in other manifestations.
EP Lab Digest
07/09/2024
Sirnaomics Press Release
HONG KONG and GERMANTOWN, Md. and SUZHOU, China, July 8, 2024 /-- Sirnaomics Ltd., a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today announced the interim results for successful completion of the second cohort of its Phase I clinical study of GalNAc-based RNAi therapeutic STP122G, targeting Factor XI as a novel form of anticoagulation agent.
EP Lab Digest
07/09/2024
Provides expanded access to FDA and prioritized review of submission
First Report Managed Care
07/09/2024
Discover how social determinants of health have historically been overlooked in healthcare, the obstacles preventing professionals from addressing them, and the potential consequences of reducing policy support in this eye-opening interview with an industry expert.
EP Lab Digest
07/09/2024
Element Science Press Release
Psych Congress Network
07/09/2024
Craig Chepke, MD, DFAPA, shares the importance of differentiating tardive dyskinesia (TD) from other movement disorders .
Lymphoma, Leukemia & Myeloma Network
07/09/2024
Michael Wang, MD, presents data from the SYMPATICO trail on the encouraging efficacy and safety of ibrutinib plus venetoclax for patients with high-risk TP53-mutated mantle cell lymphoma.
Oncology
07/09/2024
Julie Vose, MD, presents data from an optimization cohort that demonstrated improved safety of optimized epcoritamab treatment to strategically reduce CRS and ICANS among patients with R/R follicular lymphoma in the outpatient setting.
Lymphoma, Leukemia & Myeloma Network
07/09/2024
True or False: According to a 7.5-year follow-up of the LYMA trial, standard-of-care therapy of rituximab maintenance following autologous stem cell transplantation continued to demonstrate benefits to efficacy and safety outcomes among first-line young patients with mantle cell lymphoma.
Lymphoma, Leukemia & Myeloma Network
07/09/2024
The U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel for adult patients with relapsed or refractory MCL who have received at least 2 prior lines of systemic therapy including a BTK inhibitor.